<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>VECAMYL- mecamylamine hydrochloride tablet </strong><br>Turing Pharmaceuticals<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_a783b2f3-e2f3-4543-b3d0-699e5e38592f"></a><a name="section-1"></a><p></p>
<h1>Description</h1>
<p class="First">Mecamylamine HCl is a potent, oral antihypertension agent and <span class="product-label-link" type="condition" conceptid="72712" conceptname="Synovial cyst">ganglion</span> blocker, and is a secondary amine. It is N,2,3,3-tetramethyl-bicyclo [2.2.1] heptan- 2 -amine hydrochloride. Its empirical formula is C<span class="Sub">11</span>H<span class="Sub">21</span>N •  HCl and its structural formula is:</p>
<div class="Figure">
<a name="id9128300"></a><img alt="Mecamylamine HCl MF" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0774cc48-7287-4093-91d6-9df41a81408a&amp;name=image-01.jpg">
</div>
<p>It is a white, odorless, o r practically odorless, crystalline powder, is highly stable, soluble in water and has a molecular weight of 203.75.Mecamylamine HCl is supplied as tablets for oral use, each containing 2.5 mg mecamylamine HCl. Inactive ingredients are calcium phosphate, D&amp;C Yellow 10, FD&amp;C Yellow 6, lactose, magnesium stearate, cornstarch, and talc. </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_a52443bc-3d94-429c-a03c-3b78f69ce82b"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Mecamylamine HCl reduces blood pressure in both normotensive and hypertensive individuals. It has a gradual onset of action (1/2 to 2 hours) and a long-lasting effect (usually 6 to 12 hours or more). A small oral dosage often produces a smooth and predictable reduction of blood pressure. Although this antihypertensive effect is predominantly orthostatic, the supine blood pressure is also significantly reduced.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_e1b334f3-0168-4695-942c-93e27537bf01"></a><a name="section-2.1"></a><p></p>
<h2>Pharmacokinetics and Metabolism</h2>
<p class="First">Mecamylamine HCl is almost completely absorbed from the gastrointestinal tract, resulting in consistent lowering of blood pressure in most patients with hypertensive cardiovascular disease. Mecamylamine HCl is excreted slowly in the urine in the unchanged form. The rate of its renal elimination is influenced markedly by urinary pH. Alkalinization of the urine reduces, and acidification promotes, renal excretion of mecamylamine.</p>
<p>Mecamylamine HCl crosses the blood-brain and placental barriers</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_d6d7e1f9-c65a-496a-b2f7-1985e6090ad6"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">For the management of moderately severe to severe <span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">essential hypertension</span> and in uncomplicated cases of <span class="product-label-link" type="condition" conceptid="4289933" conceptname="Malignant hypertension">malignant hypertension</span></p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_11cd88a4-aeb2-47c6-9dcd-91d32be112a2"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Mecamylamine HCl should not be used in mild, moderate, labile <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and may prove unsuitable in uncooperative patients. It is contraindicated in coronary insufficiency or recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>.</p>
<p>Mecamylamine HCl should be given with great discretion, if at all, when <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> is manifested by a rising or elevated BUN. The drug is contraindicated in <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">uremia</span>. Patients receiving antibiotics and sulfonamides should generally not be treated with <span class="product-label-link" type="condition" conceptid="72712" conceptname="Synovial cyst">ganglion</span> blockers. Other contraindications are <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, organic <span class="product-label-link" type="condition" conceptid="4273754" conceptname="Pyloric stenosis">pyloric stenosis</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the product</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="ID_4faf5564-e902-4273-b7c9-8a98562d51a9"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Mecamylamine, a secondary amine, readily penetrates into the brain and thus may produce central nervous system effects. <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span>, choreiform movements, mental aberrations, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> may occur rarely. These have occurred most often when large doses of Mecamylamine HCl were used, especially in patients with cerebral or <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>.</p>
<p>When <span class="product-label-link" type="condition" conceptid="72712" conceptname="Synovial cyst">ganglion</span> blockers or other potent antihypertensive drugs are discontinued suddenly, hypertensive levels return. In patients with <span class="product-label-link" type="condition" conceptid="4289933" conceptname="Malignant hypertension">malignant hypertension</span> and others, this may occur abruptly and may cause fatal cerebral vascular <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accidents</span> or acute <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. When Mecamylamine HCl  is withdrawn, this should be done gradually and other antihypertensive therapy usually must be substituted. On the other hand, the effects of Mecamylamine HCl  sometimes may last from hours to days after therapy is discontinued.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="ID_67b61657-a66f-4ca0-b475-a70e426d097d"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="ID_2ef0dba6-8aba-42d9-973c-8f56632fdffd"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">The patient's condition should be evaluated carefully, particularly as to renal and cardiovascular function. When renal, cerebral, or coronary blood flow is deficient, any additional impairment, which might result from added <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, must be avoided. The use of Mecamylamine HCl in patients with marked cerebral and coronary <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">arteriosclerosis</span> or after a recent cerebral <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accident</span> requires caution.</p>
<p>The action of Mecamylamine HCl may be potentiated by excessive heat, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, pregnancy, anesthesia, surgery, vigorous exercise, other antihypertensive drugs, alcohol, and <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">salt depletion</span> as a result of diminished intake or increased excretion due to <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, excessive <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, or diuretics.</p>
<p>During therapy with Mecamylamine HCl, sodium intake should not be restricted but, if necessary, the dosage of the <span class="product-label-link" type="condition" conceptid="72712" conceptname="Synovial cyst">ganglion</span> blocker must be adjusted.</p>
<p>Since <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> may occur in patients on <span class="product-label-link" type="condition" conceptid="72712" conceptname="Synovial cyst">ganglion</span> blockers, caution is required in patients with <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>, <span class="product-label-link" type="condition" conceptid="433813" conceptname="Bladder neck obstruction">bladder neck obstruction</span>, and <span class="product-label-link" type="condition" conceptid="195590" conceptname="Urethral stricture">urethral stricture</span>.</p>
<p>Frequent <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose bowel</span> movements with abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span> and decreased <span class="product-label-link" type="condition" conceptid="197377" conceptname="Abnormal bowel sounds">borborygmi</span> may be the first signs of <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>. If these are present, Mecamylamine HCl should be discontinued immediately and remedial steps taken</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_1a4d3dbb-d1a7-4437-9765-023299675c2a"></a><a name="section-6.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Mecamylamine HCl may cause <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>, especially when rising from a lying or sitting position. This effect may be increased by alcoholic beverages, exercise, or during hot weather. Getting up slowly may help alleviate such a</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_974e69b1-80f1-45a2-bd06-b2a6488b1851"></a><a name="section-6.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Patients receiving antibiotics and sulfonamides generally should not be treated with <span class="product-label-link" type="condition" conceptid="72712" conceptname="Synovial cyst">ganglion</span> blockers.</p>
<p>The action of Mecamylamine HCl  may be potentiated by anesthesia, other antihypertensive drugs and alcohol.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_2ddb1cdb-a224-4548-b3e0-5a502543f188"></a><a name="section-6.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term studies in animals have not been performed to evaluate the effects upon fertility, mutagenic or carcinogenic potential of Mecamylamine</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_c77bc316-623c-498a-97e1-745fe3eb53b4"></a><a name="section-6.5"></a><p></p>
<h2>Pregnancy</h2>
<p class="First"><span class="Italics">Pregnancy Category C.</span> Animal reproduction studies have not been conducted with Mecamylamine HCl. It is not known whether Mecamylamine HCl can cause fetal harm when given to a pregnant woman or can affect reproductive capacity. Mecamylamine HCl should be given to a pregnant woman only if clearly needed</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_0bb061f2-10b3-4df3-b5f4-5385c7169069"></a><a name="section-6.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Because of the potential for serious adverse reactions in nursing infants from Mecamylamine HCl, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_242ed2c2-8ad4-4133-8c8f-1952df371d50"></a><a name="section-6.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_8ef12b85-e035-4b61-b3d7-338a7f75622e"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions have been reported and within each category are listed in order of decreasing severity.</p>
<p><span class="Italics">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">Ileus</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (sometimes preceded by small, frequent liquid stools), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span> and dryness of mouth.</p>
<p><span class="Italics">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="4250121" conceptname="Dizziness on standing up">Orthostatic dizziness</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>.</p>
<p><span class="Italics">Nervous System/Psychiatric:</span> <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span>, choreiform movements, mental aberrations, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span> (see <a href="#ID_4faf5564-e902-4273-b7c9-8a98562d51a9">WARNINGS</a>)</p>
<p><span class="Italics">Respiratory:</span> Interstitial <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> and <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span>.</p>
<p><span class="Italics">Urogenital:</span> <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary retention</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, decreased libido.</p>
<p><span class="Italics">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">dilated pupils</span>.</p>
<p><span class="Italics">Miscellaneous:</span> <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, sedation.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_b8521971-7d8a-4417-8a1c-91a4e5909246"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Signs of overdosage include: <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (which may progress to peripheral <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">vascular collapse</span>), <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, or <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>. A rise in intraocular pressure may occur.</p>
<p>Pressor amines may be used to counteract excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. Since patients being treated with <span class="product-label-link" type="condition" conceptid="72712" conceptname="Synovial cyst">ganglion</span> blockers are more than normally reactive to pressor amines, small doses of the latter are recommended to avoid excessive response.</p>
<p>The oral LD<span class="Sub">50 </span>of Mecamylamine HCl in the mouse is 92 mg/kg.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_eb3ea99a-8782-4c2b-9f91-cfa469fe72bc"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Therapy is usually started with one 2.5 mg tablet of Mecamylamine HCl twice a day. This initial dosage should be modified by increments of one 2.5 mg tablet at intervals of not less than 2 days until the desired blood pressure response occurs (the criterion being a dosage just under that which causes signs of mild <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>).</p>
<p>The average total daily dosage of Mecamylamine HCl is 25 mg, usually in three divided doses. However, as little as 2.5 mg daily may be sufficient to control <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> in some patients. A range of two to four or even more doses may be required in severe cases when smooth control is difficult to obtain. In severe or urgent cases, larger increments at smaller intervals may be needed. Partial tolerance may develop in certain patients, requiring an increase in the daily dosage of Mecamylamine HCl.</p>
<p>Administration of Mecamylamine HCl after meals may cause a more gradual absorption and smoother control of excessively high blood pressure. The timing of doses in relation to meals should be consistent. Since the blood pressure response to antihypertensive drugs is increased in the early morning, the larger dose should be given at noontime and perhaps in the evening. The morning dose, as a rule, should be relatively small and in some instances may even be omitted.</p>
<p>The <span class="Italics">initial regulation of dosage</span> should be determined by blood pressure readings in the erect position at the time of maximal effect of the drug, as well as by other signs and symptoms of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>.</p>
<p>The <span class="Italics">effective maintenance dosage</span> should be regulated by blood pressure readings in the erect position and by limitation of dosage to that which causes slight faintness or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> in this position. If the patient or a relative can use a sphygmomanometer, instructions may be given to reduce or omit a dose if readings <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> below a designated level or if faintness or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> occurs. <span class="Italics">However, no change should be instituted without the knowledge of the physician.</span></p>
<p>Close supervision and education of the patient, as well as critical adjustment of dosage, are essential to successful therapy. </p>
<p><span class="Italics">Other Antihypertensive Agents</span></p>
<p>When Mecamylamine HCl is given with other antihypertensive drugs, the dosage of these other agents, as well as that of Mecamylamine HCl, should be reduced to avoid excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. However, thiazides should be continued in their usual dosage, while that of Mecamylamine HCl is decreased by at least 50 percent.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_31218d6a-6feb-409e-a04a-30e927610221"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Vecamyl® (MECAMYLAMINE Hydrochloride Tablets, USP) are slightly yellow, round, compressed tablets, coded MP on one side and 2.5 on the other side. They are supplied as follows:</p>
<p><span class="Bold">NDC</span> 69413-558-40 in bottles of 100. </p>
<p><span class="Bold">STORAGE CONDITION</span></p>
<p>Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F)<br> [see USP Controlled Room [Temperature]</p>
<p>Manufactured by: Nexgen Pharma, Inc.  Colorado Springs, CO 80906</p>
<p>Distributed by:  Turing Pharmaceuticals LLC, New York, NY 10036</p>
<p>                                                                                                                                                                                     Rev.04/15</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_c5f7749a-5810-4ec2-8c10-36b3a0a0aee8"></a><a name="section-11"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure">
<a name="id9123649"></a><img alt="Turing 100s Container Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0774cc48-7287-4093-91d6-9df41a81408a&amp;name=image-02.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VECAMYL 		
					</strong><br><span class="contentTableReg">mecamylamine hydrochloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:69413-558</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MECAMYLAMINE HYDROCHLORIDE</strong> (MECAMYLAMINE) </td>
<td class="formItem">MECAMYLAMINE HYDROCHLORIDE</td>
<td class="formItem">2.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CALCIUM PHOSPHATE, DIBASIC, DIHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Talc</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (YELLOW) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (ROUND) </td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">MP;2;5</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:69413-558-40</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA204054</td>
<td class="formItem">03/19/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Turing Pharmaceuticals
							(079604693)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 4/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>bd4c42a7-7266-4336-8ff3-dd56d9da6eb9</div>
<div>Set id: 0774cc48-7287-4093-91d6-9df41a81408a</div>
<div>Version: 3</div>
<div>Effective Time: 20150430</div>
</div>
</div> <div class="DistributorName">Turing Pharmaceuticals</div></p>
</body></html>
